[Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer].
The standard treatment for advanced ovarian cancer consist in complete surgical debulking and intravenous platin and taxane based chemotherapy. Despite research efforts, a lot of patients still die from peritoneal carcinomatosis. The aim of our work was to present the state of art about intraperitoneal chemotherapy. Intraperitoneal chemotherapy (IPC): three multi-institutional randomised trials showed that platin based IPC gave better results in term of overall and disease free survival when compared to standard intravenous treatment. Even so, IPC is not yet becoming a new international standard of treatment because a high rate of morbidity. Hyperthermic Intraperitoneal chemotherapy (HIPEC) represents an innovative alternative to IPC. HIPEC is based on a complete surgical debulking without any visible mass and an intraperitoneal chemotherapy with synergy of hyperthermia. Phase II trails have shown its feasibility. Randomised trials are needed to assess its efficiency in improving survival.
Classe
J-M
JM
Département de chirurgie oncologique, centre René-Gauducheau, boulevard J.-Monod, 44805 Nantes-Saint-Herblain, France. jm-classe@nantes.fnclcc.fr
Muller
M
M
Frenel
J-S
JS
Berton Rigaud
D
D
Ferron
G
G
Jaffré
I
I
Gladieff
L
L
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010537:Peritoneum / Q000187:drug effects*; D017671:Platinum Compounds / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000008:administration & dosage
D000970:Antineoplastic Agents; D017671:Platinum Compounds; D043823:Taxoids